Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM: Positive Airway Pressure on the Mucolytic Effects of NAC
NCT06152653Phase 4Active, not recruiting
- Sponsor
- University of California, San Francisco
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of acetylcysteine inhalation solution in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in mucus plug score at 6 weeks. Started Apr 2024; status: active, not recruiting.
02
Drugs
acetylcysteine inhalation solution
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06152653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152653.